Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Steatohepatitis
ADR ID BADD_A09315
ADR Hierarchy
09      Hepatobiliary disorders
09.01      Hepatic and hepatobiliary disorders
09.01.07      Hepatocellular damage and hepatitis NEC
09.01.07.024      Steatohepatitis
14      Metabolism and nutrition disorders
14.08      Lipid metabolism disorders
14.08.04      Lipid metabolism and deposit disorders NEC
14.08.04.020      Steatohepatitis
Description Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS. | Inflammation of the liver related to lipid accumulation in fatty liver. [MeSH]
MedDRA Code 10076331
MeSH ID D005234
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Steatohepatitis | Fatty Liver | Liver, Fatty | Steatohepatitides | Steatosis of Liver | Visceral Steatosis | Steatoses, Visceral | Steatosis, Visceral | Visceral Steatoses | Liver Steatosis | Liver Steatoses | Steatoses, Liver | Steatosis, Liver
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Not AvailableNot AvailableNot Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00349Capecitabine0.000799%
BADD_D01009Gemcitabine0.000208%
BADD_D01418Methotrexate0.000560%
BADD_D01834Prednisone0.000080%
The 1th Page    1    Total 1 Pages